The 2023 <scp>ACR</scp>/<scp>EULAR</scp> Antiphospholipid Syndrome Classification Criteria

Barbhaiya, Medha; Zuily, Stéphane; Naden, Ray; Hendry, Alison; Manneville, Florian; Amigo, Mary‐Carmen; Amoura, Zahir; Andrade, Danieli; Andréoli, Laura; Artım-Esen, Bahar; Atsumi, Tatsuya; Avčin, Tadej; Michael Belmont, H.; Laura Bertolaccini, María; Ware Branch, D.; Carvalheiras, Graziela; Casini, Alessandro; Cervera, Ricard; Cohen, Hannah; Costedoat‐Chalumeau, N.; Crowther, Mark; Ramires de Jesús, Guilherme; Delluc, Aurélien; Desai, Sheetal; De Sancho, Maria; Devreese, Katrien; Diz Küçükkaya, Reyhan; Duarte‐García, Alí; Françès, Camille; García, David; Gris, Jean‐Christophe; Jordan, Natasha; Karp Leaf, Rebecca; Kello, Nina; S. Knight, Jason; A. Laskin, Carl; Ian Lee, Alfred; Legault, Kimberly; Levine, Steve; A. Levy, Roger; Limper, Maarten; D. Lockshin, Michael; Mayer-Pickel, K; Musial, Jack; Luigi Meroni, Pier; Orsolini, Giovanni; L. Ortel, Thomas; Pengo, Vittorio; Petri, Michelle; Pons‐Estel, Guillermo; A. Gómez‐Puerta, José; Raimboug, Quentin; Roubey, Robert; Sanna, Giovanni; V. Seshan, Surya; Sciascia, Savino; G. Tektonidou, Maria; Tincani, Anǵela; Wahl, Denis; Willis, Rohan; Yelnik, Cécile; Zuily, Catherine; Guillemin, Françis; H. Costenbader, Karen; Erkan, Doruk; ACR/EULAR APS Classification Criteria Collaborators, the

doi:10.1002/art.42624

Public

The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

Published in Arthritis & Rheumatology • Aug 28, 2023

Authors:

Medha Barbhaiya

Stéphane Zuily

Ray Naden

Abstract

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included 4 phases: 1)...

Subject

Antiphospholipid syndrome

Medicine

Immunology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!